Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: The 3-month effect of zoledronic acid, denosumab or teriparatide treatment

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 3, 2015, Pages 299-306

  Anastasilakis, Athanasios D ^a   Polyzos, Stergios A ^b   Makras, Polyzois ^c   Gkiomisi, Athina ^a   Sakellariou, Grigorios ^a   Savvidis, Matthaios ^a   Papatheodorou, Athanasios ^c   Kokkoris, Panagiotis ^c   Terpos, Evangelos ^d  

^a 424 General Army Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bisphosphonate; Denosumab; Osteoporosis; Plexin; Semaphorin; Teriparatide

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CREATININE; DENOSUMAB; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLEXIN; PLEXIN B1; SEMAPHORIN; SEMAPHORIN 4D; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; 25-HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CD100 ANTIGEN; CELL SURFACE RECEPTOR; IMIDAZOLE DERIVATIVE; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; NERVE PROTEIN; PLXNB1 PROTEIN, HUMAN; VITAMIN D;

AGED; BLOOD SAMPLING; BODY MASS; BONE DENSITY; BONE MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; HUMAN; INTERVENTION STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; OPEN STUDY; OSTEOLYSIS; PARALLEL DESIGN; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; LUMBAR VERTEBRA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LUMBAR VERTEBRAE; MIDDLE AGED; NERVE TISSUE PROTEINS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RECEPTORS, CELL SURFACE; SEMAPHORINS; TERIPARATIDE; VITAMIN D;

EID: 84923072347     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.983078     Document Type: Review

References (12)

1. Takamatsu H, Kumanogoh A. Diverse roles for semaphorin-plexin signaling in the immune system. Trends Immunol 2012;33(3):127-35
2. Negishi-Koga T, Shinohara M, Komatsu N, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011;17(11):1473-80
3. Dacquin R, Domenget C, Kumanogoh A, et al. Control of bone resorption by semaphorin 4D is dependent on ovarian function. PLoS One 2011;6(10):e26627
4. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22
5. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65
6. Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-41
7. Makras P, Vaiopoulos G, Lyritis GP. 2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 2012;12(1):38-42
8. Negishi-Koga T, Takayanagi H. Bone cell communication factors and Semaphorins. Bonekey Rep 2012;1:183
9. Anastasilakis AD, Polyzos SA, Gkiomisi A, et al. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of näive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab 2013;98(8):3206-12
10. Zhang Y, Wei L, Miron RJ, et al. Anabolic bone formation via a site specific bone targeting delivery system by interfering with semaphorin 4D expression. J Bone Miner Res 2014; Epub ahead of print
11. Uyanne J, Calhoun CC, Le AD. Antiresorptive drug-related osteonecrosis of the jaw. Dent Clin North Am 2014;58(2):369-84
12. Pazianas M, Smith R. Commentary: drug-associated atypical femoral fractures (DaAFFs): balancing the facts. J Clin Endocrinol Metab 2014;99(7):2340-2